![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MYL6 |
Gene summary for MYL6 |
![]() |
Gene information | Species | Human | Gene symbol | MYL6 | Gene ID | 4637 |
Gene name | myosin light chain 6 | |
Gene Alias | ESMLC | |
Cytomap | 12q13.2 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | P60660 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4637 | MYL6 | CA_HPV_1 | Human | Cervix | CC | 1.11e-03 | -1.30e-01 | 0.0264 |
4637 | MYL6 | CA_HPV_2 | Human | Cervix | CC | 6.54e-05 | -1.60e-01 | 0.0391 |
4637 | MYL6 | CA_HPV_3 | Human | Cervix | CC | 2.19e-02 | -3.12e-02 | 0.0414 |
4637 | MYL6 | CCI_1 | Human | Cervix | CC | 8.12e-48 | -1.53e+00 | 0.528 |
4637 | MYL6 | CCI_2 | Human | Cervix | CC | 1.42e-33 | -1.26e+00 | 0.5249 |
4637 | MYL6 | CCI_3 | Human | Cervix | CC | 7.78e-55 | -1.52e+00 | 0.516 |
4637 | MYL6 | CCII_1 | Human | Cervix | CC | 1.78e-62 | -1.32e+00 | 0.3249 |
4637 | MYL6 | Tumor | Human | Cervix | CC | 3.76e-04 | -1.30e-01 | 0.1241 |
4637 | MYL6 | sample3 | Human | Cervix | CC | 6.09e-25 | -1.81e-01 | 0.1387 |
4637 | MYL6 | H2 | Human | Cervix | HSIL_HPV | 4.56e-06 | -2.48e-01 | 0.0632 |
4637 | MYL6 | L1 | Human | Cervix | CC | 1.47e-03 | -2.52e-01 | 0.0802 |
4637 | MYL6 | T3 | Human | Cervix | CC | 3.30e-22 | -1.63e-01 | 0.1389 |
4637 | MYL6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.89e-44 | 9.80e-01 | 0.0155 |
4637 | MYL6 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.77e-51 | 2.10e+00 | -0.1808 |
4637 | MYL6 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.83e-11 | 1.06e+00 | 0.0216 |
4637 | MYL6 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.99e-51 | 2.00e+00 | -0.0811 |
4637 | MYL6 | HTA11_78_2000001011 | Human | Colorectum | AD | 7.48e-16 | 9.07e-01 | -0.1088 |
4637 | MYL6 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.73e-77 | 1.97e+00 | -0.1954 |
4637 | MYL6 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.79e-19 | 3.17e+00 | -0.2602 |
4637 | MYL6 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.81e-24 | 2.30e+00 | -0.2196 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
GO:006053715 | Oral cavity | EOLP | muscle tissue development | 77/2218 | 403/18723 | 1.37e-05 | 2.31e-04 | 77 |
GO:001470614 | Oral cavity | EOLP | striated muscle tissue development | 72/2218 | 384/18723 | 4.87e-05 | 6.43e-04 | 72 |
GO:00605384 | Oral cavity | EOLP | skeletal muscle organ development | 35/2218 | 166/18723 | 4.65e-04 | 4.08e-03 | 35 |
GO:00075195 | Oral cavity | EOLP | skeletal muscle tissue development | 32/2218 | 155/18723 | 1.15e-03 | 8.37e-03 | 32 |
GO:00075176 | Oral cavity | EOLP | muscle organ development | 57/2218 | 327/18723 | 1.76e-03 | 1.15e-02 | 57 |
GO:00030128 | Oral cavity | EOLP | muscle system process | 71/2218 | 452/18723 | 7.83e-03 | 3.73e-02 | 71 |
GO:006053723 | Oral cavity | NEOLP | muscle tissue development | 75/2005 | 403/18723 | 1.22e-06 | 3.15e-05 | 75 |
GO:001470621 | Oral cavity | NEOLP | striated muscle tissue development | 69/2005 | 384/18723 | 1.11e-05 | 2.06e-04 | 69 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
GO:000751912 | Oral cavity | NEOLP | skeletal muscle tissue development | 29/2005 | 155/18723 | 1.97e-03 | 1.32e-02 | 29 |
GO:003004810 | Oral cavity | NEOLP | actin filament-based movement | 24/2005 | 127/18723 | 4.02e-03 | 2.29e-02 | 24 |
GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
GO:00300489 | Prostate | BPH | actin filament-based movement | 38/3107 | 127/18723 | 1.31e-04 | 1.18e-03 | 38 |
GO:00147066 | Prostate | BPH | striated muscle tissue development | 91/3107 | 384/18723 | 1.90e-04 | 1.57e-03 | 91 |
GO:00030127 | Prostate | BPH | muscle system process | 103/3107 | 452/18723 | 3.54e-04 | 2.62e-03 | 103 |
GO:00605383 | Prostate | BPH | skeletal muscle organ development | 40/3107 | 166/18723 | 8.09e-03 | 3.52e-02 | 40 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0492111 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa045302 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
hsa045303 | Colorectum | SER | Tight junction | 59/1580 | 169/8465 | 3.24e-07 | 5.98e-06 | 4.34e-06 | 59 |
hsa045304 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
hsa045305 | Colorectum | MSS | Tight junction | 66/1875 | 169/8465 | 4.10e-07 | 6.25e-06 | 3.83e-06 | 66 |
hsa045306 | Colorectum | MSI-H | Tight junction | 31/797 | 169/8465 | 2.08e-04 | 2.80e-03 | 2.35e-03 | 31 |
hsa045307 | Colorectum | MSI-H | Tight junction | 31/797 | 169/8465 | 2.08e-04 | 2.80e-03 | 2.35e-03 | 31 |
hsa045308 | Colorectum | FAP | Tight junction | 60/1404 | 169/8465 | 1.40e-09 | 9.33e-08 | 5.67e-08 | 60 |
hsa04270 | Colorectum | FAP | Vascular smooth muscle contraction | 33/1404 | 134/8465 | 1.05e-02 | 3.74e-02 | 2.28e-02 | 33 |
hsa045309 | Colorectum | FAP | Tight junction | 60/1404 | 169/8465 | 1.40e-09 | 9.33e-08 | 5.67e-08 | 60 |
hsa042701 | Colorectum | FAP | Vascular smooth muscle contraction | 33/1404 | 134/8465 | 1.05e-02 | 3.74e-02 | 2.28e-02 | 33 |
hsa0453026 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
hsa04530112 | Endometrium | AEH | Tight junction | 54/1197 | 169/8465 | 1.99e-09 | 3.80e-08 | 2.78e-08 | 54 |
hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYL6 | SNV | Missense_Mutation | c.372A>C | p.Glu124Asp | p.E124D | P60660 | protein_coding | deleterious(0.04) | possibly_damaging(0.821) | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD | |
MYL6 | SNV | Missense_Mutation | c.397G>C | p.Glu133Gln | p.E133Q | P60660 | protein_coding | deleterious(0.04) | possibly_damaging(0.615) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
MYL6 | SNV | Missense_Mutation | rs747003745 | c.217N>G | p.Met73Val | p.M73V | P60660 | protein_coding | tolerated(0.1) | benign(0.015) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYL6 | SNV | Missense_Mutation | novel | c.209T>G | p.Phe70Cys | p.F70C | P60660 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MYL6 | SNV | Missense_Mutation | rs372692919 | c.449N>T | p.Ser150Leu | p.S150L | P60660 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MYL6 | SNV | Missense_Mutation | novel | c.42G>T | p.Glu14Asp | p.E14D | P60660 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MYL6 | SNV | Missense_Mutation | c.337N>G | p.Leu113Val | p.L113V | P60660 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-33-4547-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |